JAK-STAT pathway inhibitors in dermatology

Página do item simplificado
dc.contributor.authorMiot, Hélio Amante [UNESP]
dc.contributor.authorCriado, Paulo Ricardo
dc.contributor.authorde Castro, Caio César Silva
dc.contributor.authorIanhez, Mayra
dc.contributor.authorTalhari, Carolina
dc.contributor.authorRamos, Paulo Müller [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionCentro Universitário Faculdade de Medicina do ABC
dc.contributor.institutionFaculdade de Ciências Médicas de Santos
dc.contributor.institutionHospital de Dermatologia Sanitária do Paraná
dc.contributor.institutionPontifícia Universidade Católica do Paraná
dc.contributor.institutionUniversidade Federal de Goiás (UFG)
dc.contributor.institutionUniversidade do Estado do Amazonas
dc.date.accessioned2023-07-29T13:55:44Z
dc.date.available2023-07-29T13:55:44Z
dc.date.issued2023-01-01
dc.description.abstractThe JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice.en
dc.description.affiliationDepartment of Dermatology Faculdade de Medicina Universidade Estadual Paulista, SP
dc.description.affiliationCentro Universitário Faculdade de Medicina do ABC, SP
dc.description.affiliationFaculdade de Ciências Médicas de Santos, SP
dc.description.affiliationHospital de Dermatologia Sanitária do Paraná, PR
dc.description.affiliationEscola de Medicina Pontifícia Universidade Católica do Paraná, PR
dc.description.affiliationDepartment of Tropical Medicine and Dermatology Instituto de Patologia Tropical e Saúde Pública Universidade Federal de Goiás, GO
dc.description.affiliationDepartment of Dermatology Universidade do Estado do Amazonas, AM
dc.description.affiliationUnespDepartment of Dermatology Faculdade de Medicina Universidade Estadual Paulista, SP
dc.identifierhttp://dx.doi.org/10.1016/j.abd.2023.03.001
dc.identifier.citationAnais Brasileiros de Dermatologia.
dc.identifier.doi10.1016/j.abd.2023.03.001
dc.identifier.issn1806-4841
dc.identifier.issn0365-0596
dc.identifier.scopus2-s2.0-85159902808
dc.identifier.urihttp://hdl.handle.net/11449/248859
dc.language.isoeng
dc.relation.ispartofAnais Brasileiros de Dermatologia
dc.sourceScopus
dc.subjectAlopecia areata
dc.subjectAtopic dermatitis
dc.subjectJanus Kinase Inhibitors
dc.subjectPsoriasis
dc.subjectTreatment
dc.subjectVitiligo
dc.titleJAK-STAT pathway inhibitors in dermatologyen
dc.typeResenha
unesp.author.orcid0000-0002-2596-9294[1]
unesp.author.orcid0000-0001-9785-6099 0000-0001-9785-6099[2]
unesp.author.orcid0000-0001-9767-5765 0000-0001-9767-5765[3]
unesp.author.orcid0000-0003-3604-3128[4]
unesp.author.orcid0000-0003-2283-069X[5]
unesp.author.orcid0000-0002-1561-414X[6]

Arquivos

Coleções

Artigos - Dermatologia e Radioterapia - FMB